- Home
- EPSN vs CRDF Comparison
EPSN vs CRDF Comparison
Compare EPSN & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPSN
- CRDF
- Stock Information
- Founded
- EPSN 2005
- CRDF 1999
- Country
- EPSN Canada
- CRDF United States
- Employees
- EPSN N/A
- CRDF N/A
- Industry
- EPSN Oil & Gas Production
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EPSN Energy
- CRDF Health Care
- Exchange
- EPSN Nasdaq
- CRDF Nasdaq
- Market Cap
- EPSN 155.9M
- CRDF 169.6M
- IPO Year
- EPSN N/A
- CRDF N/A
- Fundamental
- Price
- EPSN $7.27
- CRDF $3.51
- Analyst Decision
- EPSN Strong Buy
- CRDF Strong Buy
- Analyst Count
- EPSN 1
- CRDF 4
- Target Price
- EPSN $7.00
- CRDF $12.25
- AVG Volume (30 Days)
- EPSN 82.0K
- CRDF 860.0K
- Earning Date
- EPSN 05-14-2025
- CRDF 05-08-2025
- Dividend Yield
- EPSN 3.42%
- CRDF N/A
- EPS Growth
- EPSN N/A
- CRDF N/A
- EPS
- EPSN 0.20
- CRDF N/A
- Revenue
- EPSN $39,699,172.00
- CRDF $587,000.00
- Revenue This Year
- EPSN $41.35
- CRDF N/A
- Revenue Next Year
- EPSN N/A
- CRDF N/A
- P/E Ratio
- EPSN $35.87
- CRDF N/A
- Revenue Growth
- EPSN 35.21
- CRDF N/A
- 52 Week Low
- EPSN $4.95
- CRDF $2.01
- 52 Week High
- EPSN $7.54
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- EPSN 58.74
- CRDF 68.03
- Support Level
- EPSN $6.91
- CRDF $2.81
- Resistance Level
- EPSN $7.35
- CRDF $3.08
- Average True Range (ATR)
- EPSN 0.26
- CRDF 0.21
- MACD
- EPSN 0.02
- CRDF 0.08
- Stochastic Oscillator
- EPSN 64.84
- CRDF 90.55
About EPSN Epsilon Energy Ltd. Common Share
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.